Navigating Through Screening of Urological Cancers

Introduction

Prostate cancer is a type of non-skin cancer causing more deaths in men than any other cancer (except lung cancer). It is more commonly seen in African Americans than in white men. There is no standard test for screening for prostate cancer. However, some of the commonly done tests are discussed below.

What Does Prostate Cancer Screening Involve?

Cancer screening means looking for cancer before the appearance of signs or symptoms. Finding cancer at an early stage provides better chances for successfully treating it. The overall goal of screening is to reduce the number of people who develop the disease and die from it and eliminate death rates.

Prostate cancer screening aims to detect cancer at the earliest possible stage before it spreads. If the result of screening tests is found to be abnormal, further tests are conducted to determine whether an individual has cancer. These additional tests are called diagnostic tests. Prostate cancer screening is recommended for adults, particularly those over the age of 50 or earlier, if there is a family history or other risk factors.

Guidelines for Prostate Cancer Screening:

Prostate-Specific Antigen (PSA) Test: PSA for prostate cancer screening is a blood test that measures the level of prostate-specific antigen (PSA) in the blood. Elevated PSA levels can indicate a higher likelihood of prostate cancer. Prostate-specific antigen levels may also be elevated in certain conditions, such as:

• Certain medications.

• An enlarged prostate gland.

• Infection in the gland.

• Certain medical procedures.

Since many factors affect the levels, consulting the doctor and following the advice is the best. If the doctor finds the levels abnormal, they may recommend a biopsy.

For the procedure, a blood sample is taken and analyzed for PSA levels.

1. Results Interpretation: High PSA levels can be associated with prostate cancer, but it may also be caused by benign prostatic hyperplasia (BPH) or prostatitis. Age-specific PSA thresholds are applied to increase the specificity and decrease the false positives. A PSA level below 4.0 ng/mL (nanogram per milliliter) is generally considered normal, though this can vary depending on individual factors. Levels above 4.0 ng/mL may indicate a higher likelihood of prostate cancer, though other conditions like an enlarged prostate or infection can also cause elevated PSA levels.

2. Advantages: The advantages of prostate-specific antigen tests are:

• Elevated levels are associated with prostate cancer that is most likely to metastasize (spread to other body parts).

• Early detection and treatment can help cancer before it becomes life-threatening.

3.Limitations:

• False-positive results due to underlying disease are a significant drawback of these tests. Certain conditions, such as enlargement of the prostate gland or infection (prostatitis), may show higher levels of prostate-specific antigens. Thus, false-positive results may come up.

• False-negative results may appear that may result in delays in seeking medical treatment.

• Follow-up tests to rule out the cause of elevated levels may result in more stress, expenses, and time taking.

• This test may find a slow-growing prostate that is not troublesome, and unwanted screening may lead to treatments that are not needed.

• In some cases, finding prostate cancer may not improve a man's health or make him live longer.

• Follow-up tests, such as biopsy, may cause certain complications such as fever, pain, blood in the urine, and urinary tract infection. If the biopsy shows the patient does not have cancer, he might worry more about developing cancer in the near future.

Thus, it is recommended that people with no symptoms, who are expected to live for less than ten years, should not receive prostate-specific antigen screening.

Digital Rectal Examination (DRE):DRE is a physical examination that assesses the prostate for abnormalities. The prostate doctor will insert a gloved, lubricated finger into the rectum to inspect the prostate gland for tumors, hard spots, or abnormalities.

• Advantages: Can identify cancers that do not raise PSA levels—a non-invasive, time and painless evaluation.

• Limitations: Cancers cannot be recognized during the early stages of minute irregularities. This is somewhat subjective and sensitive to the examiner's experience.

Prostate Cancer Gene 3 (PCA3) RNA (Ribonucleic Acid) Test: A prostate cancer gene three (PCA3) ribonucleic acid (RNA) test is another test used in screening for prostate cancer in some patients. If a man has a higher level of prostate-specific antigen levels and the biopsy report does not indicate cancer and levels remain high, then this test is done. This test measures the amount of prostate cancer gene three (PCA3) ribonucleic acid (RNA) in the urine. After performing a DRE, a urine sample is extracted to measure PCA3 RNA levels.

• Advantages: It is extremely specific for prostate cancer and less dependent on other prostate conditions, especially BPH. It is useful in deciding whether a biopsy is needed, particularly when PSA results are inconclusive.

• Limitations: It is used as an auxiliary test rather than a primary screening tool.

What Are the Factors That Increase the Risk of Prostate Cancer?

The following are the main risk factors contributing to the development of prostate cancer:

• Age: Risk increases after age 50.

• Race: Black men have a higher risk than white men.

• Family History: A family history of prostate cancer, especially diagnosed before age 65, raises the risk.

• Diet: Diets high in animal fats and low in fruits and vegetables increase risk.

• Genes: BRCA1 and BRCA2 genes are linked to higher cancer risk.

Conclusion

Among other cancers, prostate cancer affects the majority of geriatric patients. Screening of cancer is done when symptoms do not appear. It majorly includes PSA tests and DRE and sometimes includes RNA tests. It also conducts diagnostic tests; hence, if the screening results do not go well, if symptoms are present, one further undergoes diagnostic tests until a biopsy confirms if someone has cancer. Screening tests should be carried out in patients with an average life expectancy of more than ten years. Early screening for prostate cancer can detect the disease at its early stages when treatment is most effective. If you are at risk, consult your healthcare provider about starting regular screenings. Early detection leads to better treatment outcomes and quality of life.